Home » Posts tagged with » Advanced solid tumors
TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]

Lilly wraps up $8bn acquisition of Loxo Oncology

US pharma giant Eli Lilly and Company (Lilly) has wrapped up its previously announced $8 billion acquisition of Connecticut-based biopharma company Loxo Oncology. Announced in January 2019, Lilly acquisition of Loxo Oncology is expected to expand the scope of the pharma giant’s oncology portfolio into precision medicines owing to the addition of a marketed therapy […]

Continue reading …
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors

US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with the Israeli genomics-based drug and diagnostic discovery company’s COM701 in advanced solid tumors. COM701 is being investigated by Compugen as an anti-PVRIG antibody while the cancer drug Opdivo is a […]

Continue reading …
Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]

Continue reading …
Compugen kickstarts phase 1 trial of cancer immunotherapy COM701

Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has been designed to target the PVRIG gene, which according to the Israeli pharma company is a novel immune checkpoint target it had identified […]

Continue reading …
Xencor launches phase 1 trial of XmAb20717 in advanced solid tumors

Xencor has launched a phase 1 clinical trial of its bispecific antibody XmAb20717, which is being developed for the treatment of multiple advanced solid tumors. The California-based biopharma company has dosed the first patient in this regard in the early-stage human trial named XmAb20717-01 (DUET-2). DUET-2 is a multiple-dose, dose-escalation trial that will determine the […]

Continue reading …